UPDATE: Citadel Securities Upgrades Questcor from Neutral to Edge Positive and Raises PT from $23 to $44

Citadel Securities has published a report on Questcor QCOR raising the price target significantly and upgrading the company's stock from Neutral to Edge Positive. In the report, Citadel Securities wrote, "We anticipate a robust ramp in Acthar revenues from Nephrotic Syndrome based on a salesforce expansion that will complete by the end of 3Q'11. For 4Q'11, we model $22MM in Acthar revenues from Nephrotic Syndrome, and $66MM in total Acthar revenues versus $59MM consensus." Citadel Securities upgraded Questcor from Neutral to Edge Positive with a price target raised from $23.00 to $44.00. Questcor closed Monday at $28.65.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorUpgradesPrice TargetAnalyst Ratingscitadel securitiesHealth CarePharmaceuticalsQuestcor Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!